4D Molecular Therapeutics (NASDAQ:FDMT) vs. NewAmsterdam Pharma (NASDAQ:NAMS) Head-To-Head Contrast
by Teresa Graham · The Cerbat Gem4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.
Valuation and Earnings
This table compares 4D Molecular Therapeutics and NewAmsterdam Pharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 4D Molecular Therapeutics | $88.24 million | 5.87 | -$140.11 million | ($2.57) | -3.86 |
| NewAmsterdam Pharma | $22.50 million | 174.99 | -$203.82 million | ($1.79) | -18.82 |
4D Molecular Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares 4D Molecular Therapeutics and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 4D Molecular Therapeutics | -182.34% | -36.83% | -32.55% |
| NewAmsterdam Pharma | -943.23% | -26.49% | -24.37% |
Insider & Institutional Ownership
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
4D Molecular Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for 4D Molecular Therapeutics and NewAmsterdam Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 4D Molecular Therapeutics | 1 | 1 | 7 | 0 | 2.67 |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
4D Molecular Therapeutics currently has a consensus target price of $29.88, indicating a potential upside of 201.46%. NewAmsterdam Pharma has a consensus target price of $48.00, indicating a potential upside of 42.52%. Given 4D Molecular Therapeutics’ higher possible upside, equities research analysts clearly believe 4D Molecular Therapeutics is more favorable than NewAmsterdam Pharma.
Summary
NewAmsterdam Pharma beats 4D Molecular Therapeutics on 8 of the 15 factors compared between the two stocks.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.